Related Experiment Videos
Gestrinone compared with mifepristone for emergency contraception: a randomized controlled trial
Shangchun Wu1, Jing Dong, Jie Cong
1From the National Research Institute For Family Planning, Beijing, People's Republic of China; the Qingdao Family Planning Research Institute, Qingdao, People's Republic of China; the UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Geneva, Switzerland; and the Department of Family Medicine, University of Illinois College of Medicine, Chicago, Illinois.
Objective:
To compare the efficacy of gestrinone with that of mifepristone for emergency contraception.
Methods:
A randomized double-blind trial was conducted in five family-planning clinics in China. We randomly assigned 998 healthy women with regular menstrual cycles and negative urine pregnancy tests who were requesting emergency contraception up to 72 hours after unprotected coitus to receive single-dose 10 mg gestrinone (n=499) or 10 mg mifepristone (n=499). We monitored them to 7 days after the expected first day of their next menstrual period. The study was powered to detect a 5% failure rate between the two regimens.
Results:
The treatment groups did not differ significantly; posttreatment pregnancy rates were 2.4% in the gestrinone group compared with 1.8% in the mifepristone group (P=.51). The majority of women menstruated the first day of expected menses, and groups did not differ regarding side effects.
Conclusion:
The effectiveness of 10 mg gestrinone is not significantly different from 10 mg mifepristone as an emergency contraceptive method.
Clinical Trial Registration:
ISRCTN Register, isrctn.org, ISRCTN87842530.
Level Of Evidence:
I.
Related Concept Videos
Intrauterine Drug Delivery Systems
Birth Control Methods
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence